YAP regulates Gli1 expression in a SMO-independent manner.
Notes: (A) Gli1 and SMO expression in MGC803 and AGS GC cells stably transfected with control-shRNA (NC) or shRNA against YAP (KD) tested using Western blot analysis. The bands were quantified and showed as the mean ± SEM of triplicate determination from three independent experiments. (B) Gli1 and SMO expression in SGC7901 and MKN45 GC cells stably transfected with empty vector (VEC) or plasmid encoding human YAP (OE) determined by Western blotting. The bands were quantified and showed as the mean ± SEM of triplicate determination from three independent experiments. (C) Gli1 expression in SGC7901 cells (VEC and YAP OE) with or without Gli1 siRNA treatment determined by Western blotting. (D) Colony formation assays to test proliferation ability of SGC7901 cells (VEC and YAP OE) with or without Gli1 siRNA treatment. (E) Transwell assays to test migration ability of SGC7901 cells (VEC and YAP OE) with or without Gli1 siRNA treatment. GAPDH as a loading control. Statistical significance was analyzed by a two-tailed, unpaired Student’s t-test. N, nonsignificant; **P < 0.01; *P < 0.05.
Abbreviations: Gli1, glioma-associated oncogene-1; SMO, smoothened homolog; GC, gastric cancer; NC, control-shRNA; KD, shRNA against YAP; VEC, empty vector; OE, plasmid encoding human YAP; SEM, standard error of the mean; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.